Angio8 (通用科技), a surgical robot startup, announced today that it had secured a Series A round of financing worth tens of millions of yuan.
Oriental Fortune Capital led this round, with participation from HWealth Capital and other investors.
Founded in December 2021 and headquartered in Shenzhen, Angio8 is committed to cutting-edge research on endovascular surgery, especially on next-generation robotics aimed at providing minimally invasive treatment for vascular disease, coronary disease and blood vessel clots in the brain.
The company specializes in an AI surgical system that fuses the virtual and real — similar to digital twin — as part of its efforts to reconstruct or simulate an environment essential to surgical procedures.
According to a press release, this will not just allow doctors to conduct pre-surgery planning and exercises, but also create a truckload of real surgical data.
These data will then feed into the AI system, to better assist surgeons in a real-life operation.
The startup is said to comprise leading medical equipment specialists and surgical robot developers. Aside from its dedication to endovascular surgery, it has applied its robotics to the treatment of other kinds of diseases.
According to the founding team, they will use the proceeds to accelerate their product R&D and reach the clinical trial stage.
Worldwide, cardiovascular diseases have emerged as the leading cause of death for men. Every year the number of people who die from cardiovascular diseases reaches a staggering 15 million, said Wang Peijun, a partner at Oriental Fortune Capital.
And as China’s population ages rapidly and as urbanization gathers pace, the population of patients stricken with cardiovascular diseases is set to expand.
Even though traditional invasive surgery has become the norm in the treatment of these diseases, its side effects are myriad.
By dissolving clots within blood vessels and bringing endovascular surgical robots to bear, Angio8 has covered multiple clinical use cases, standing out with its minimal invasion, lasting effects and fewer long-term side effects, or so the company claims.
The startup also aims to branch out into coronary and pheripheral artery diseases, further extending the applications of its surgical robot technologies.
This is to enhance procedural efficiency and effects as well as cover more lower-tier hospitals, said Wang of Oriental Fortune Capital.